Article

BRET-Based Biosensors to Measure Agonist Efficacies in Histamine H₁ Receptor-Mediated G Protein Activation, Signaling and Interactions with GRKs and β-Arrestins

Eléonore W. E. Verweij †, Reggie Bosma †, Meichun Gao, Jelle van den Bor ○, Betty Al Araaj, Sabrina M. de Munnik, Xiaoyuan Ma ○, Rob Leurs ○ and Henry F. Vischer * ○

Division of Medicinal Chemistry, Faculty of Science, Amsterdam Institute of Molecular and Life Sciences, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands; noortje.verweij@xs4all.nl (E.W.E.V.); rbosma@vu.nl (R.B.); m.c.gao@vu.nl (M.G.); j.vanden.bor@vu.nl (J.v.d.B.); bettyalaraja@hotmail.com (B.A.A.); sabrinademunnik@hotmail.com (S.M.d.M.); x.ma@vu.nl (X.M.); r.leurs@vu.nl (R.L.)
* Correspondence: h.f.vischer@vu.nl + These authors contributed equally to this work.

Abstract: The histamine H₁ receptor (H₁R) is a G protein-coupled receptor (GPCR) and plays a key role in allergic reactions upon activation by histamine which is locally released from mast cells and basophils. Consequently, H₁R is a well-established therapeutic target for antihistamines that relieve allergy symptoms. H₁R signals via heterotrimeric Gq proteins and is phosphorylated by GPCR kinase (GRK) subtypes 2, 5, and 6, consequently facilitating the subsequent recruitment of β-arrestin1 and/or 2. Stimulation of a GPCR with structurally different agonists can result in preferential engagement of one or more of these intracellular signaling molecules. To evaluate this so-called biased agonism for H₁R, bioluminescence resonance energy transfer (BRET)-based biosensors were applied to measure H₁R signaling through heterotrimeric Gq proteins, second messengers (inositol 1,4,5-triphosphate and Ca²⁺), and receptor-protein interactions (GRKs and β-arrestins) in response to histamine, 2-phenylhistamines, and histaprodifens in a similar cellular background. Although differences in efficacy were observed for these agonists between some functional readouts as compared to reference agonist histamine, subsequent data analysis using an operational model of agonism revealed only signaling bias of the agonist Br-phHA-HA in recruiting β-arrestin2 to H₁R over Gq biosensor activation.

Keywords: histamine; H₁R; GPCR; G protein; β-arrestin; GPCR kinase; BRET assay; biased signaling

1. Introduction

The histamine H₁ receptor (H₁R) is a membrane-associated G protein-coupled receptor (GPCR) that is ubiquitously expressed on vascular endothelial, smooth muscle, immune, and brain cells and involved in, for example, acute allergic reactions, uterine contraction in preterm labor, and awakening in response to the biogenic amine histamine [1,2]. Since the 1940s, H₁R became a blockbuster drug target for the treatment of allergic responses by two generations of antihistamines, with the first-generation of these antagonists also being sedative and reducing motion sickness by crossing the blood-brain barrier and acting on H₁R in the brain [3]. H₁R signals primarily through heterotrimeric Gq/11 proteins to activate the phospholipase C signaling cascade resulting in the conversion of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-triphosphate (InsP₃) and 1,2-diacylglycerol. These so-called second messengers, in turn, increase intracellular Ca²⁺ levels and protein kinase C activity, resulting in various downstream cellular responses [2]. GPCR-mediated G protein activation is attenuated by phosphorylation of the receptor at intracellular serine and/or threonine residues, resulting in the recruitment of β-arrestin1 and/or 2 that sterically hinder further G protein coupling and facilitate receptor internalization [4,5]. Indeed, H₁R recruits
both β-arrestin1 and 2 in response to histamine stimulation as revealed by bioluminescence resonance energy transfer (BRET) and split-luciferase complementation experiments to detect protein-protein interactions [6–9]. However, H1R desensitization is only mediated by β-arrestin1/2 in myometrial smooth muscle cells as revealed by knockdown of β-arrestin1 and/or 2 by siRNA [10]. G protein-coupled receptor kinases (GRK) are critically involved in the phosphorylation of GPCRs to drive β-arrestin1/2 recruitment and activity [4]. Indeed, overexpression of GRK5, GRK6, or in particular GRK2, increased the phosphorylation of H1R in human embryonic kidney (HEK)293T upon histamine stimulation [11]. Moreover, overexpression of GRK2 abolished H1R-induced InsP3 production, which required both its catalytic kinase and regulator of G protein signaling (RGS) domains, whereas GRK5 and GRK6 had limited effect [11,12]. In line, knockdown of these individual GRK subtypes by siRNA confirmed that only GRK2 plays a role in H1R desensitization in HEK293 and myometrial smooth muscle cells upon stimulation with histamine [11,12].

GPCR ligands can induce activity bias towards certain intracellular effectors at the expense of others, by stabilizing distinct active receptor conformations [13,14]. For example, the selective engagement of GRK subtypes in response to different agonists can change the phosphorylation pattern at the intracellular loops and C-tail of GPCRs and consequently dictate subsequent β-arrestin1/2-mediated activities [15–19]. For several GPCRs, biased ligands showed better therapeutic value as compared to unbiased ligands as they selectively stimulate desirable receptor-responses while omitting adverse effects regulated by the same receptor [20]. Recently, the first biased GPCR drug Oliceridine (Olinvyk™; aka TRV130) developed by biopharmaceutical company Trevena (Chesterbrook, PA, USA) was approved by the FDA as a G protein-biased µ-opioid receptor agonist for the treatment of acute pain that displayed less β-arrestin-mediated adverse effects (e.g., respiratory suppression and nausea) in comparison to morphine [21].

In this study, we employed BRET-based biosensors to measure H1R-mediated Gq signaling, protein-protein interactions with GRK2, GRK3, GRK5, GRK6, β-arrestin1, and β-arrestin2, and receptor internalization in the same cellular background. Using these BRET-based biosensors, we next aimed to explore whether 2-phenylhistamines (phHA) and histaprodifens (HP) engage different H1R responses as compared to histamine (HA) to detect potential biased signaling.

2. Results and Discussion

2.1. BRET-Based Detection of Gq Activation and Signaling by H1R

The H1R signals predominantly via heterotrimeric Gq/11 proteins to stimulate phospholipase C activity, resulting in the production of InsP3 and a subsequent increase of intracellular Ca2+ levels [2]. To monitor these signaling events in real time we used (1) a recently developed tricistronic BRET-based Gq activation sensor plasmid that measures the dissociation of Gβ3Gγ9-cpVenus heterodimer from Gaq-Nanoluc (Nluc) luciferase upon receptor activation [22]; and (2) intramolecular BRET-based InsP3 and Ca2+ conformation biosensors consisting of the InsP3-binding domain of the human type-I InsP3 receptor with a R265K mutation and a modified Cameleon D3 sensor containing the MLCK calmodulin binding peptide 13 and the D3 variant of calmodulin, respectively [23]. Stimulation of H1R with 10 µM histamine (HA) results in rapid activation of heterotrimeric Gq proteins reaching a maximum steady-state ∆BRET response within 2 min that remained constant for at least 30 min (Figure 1A). Similar rapid Gq activation by H1R in response to histamine was previously reported using a fluorescence resonance energy transfer (FRET)-based GaqGβ3Gγ2 sensor in HeLa cells [24,25]. In contrast, recruitment of the engineered mini-Gq protein to H1R was considerably slower as measured using split-NLuc luciferase complementation assay in HEK293T [26], which might be the consequence of the deletion of the membrane anchors and Gβγ-binding interface in its N-terminus [27].
Figure 1. H1R activates heterotrimeric Gq proteins, InsP3 production and Ca2+ release in response to histamine (HA). BRET measurements in HEK293T cells transiently co-expressing H1R (0.5–1 µg plasmid/dish) in combination with the heterotrimeric Gq activation sensor (2.5 µg plasmid/dish) (A,B), InsP3 (C,D) or Ca2+ (E,F) sensor (4.0–4.5 µg plasmid/dish) in real time upon stimulation with 10 µM histamine (A,C,E) or after 20-min stimulation with increasing concentrations histamine (B,D,F). InsP3 and Ca2+ cells were first stimulated with vehicle (VEH) or histamine (HA) at t = 0 min followed by a second injection of vehicle (VEH) or 10 µM mepyramine (MEP) at t = 10 min, indicated by the numbered arrows 1 and 2, respectively (C–E). Data are shown as mean ± SD from at least three independent experiments performed in triplicate.

The potency (pEC50 = 7.2 ± 0.1; mean ± SD; n = 4) of histamine to activate heterotrimeric Gq proteins in our BRET assay is approximately 4-fold lower than previously observed in a G protein-based transforming growth factor-α shedding assay (Figure 1B) [28]. Surprisingly, a 50-fold lower histamine potency was reported in essentially a similar BRET readout between Gαq-Renilla luciferase 8 (Rluc8) and the Gβ3Gγ9-green fluorescent protein sensor (Figure 1B) [28].
readout between Gαq-Renilla luciferase 8 (Rluc8) and the Gβ3γ9-green fluorescent protein 2 (GFP2) heterodimer (called TRUPATH) in H1R expressing HEK293T cells [29], which might be the consequence to different protein expression levels by using a three plasmids-based sensor setup as compared to the single tricistronic biosensor plasmid in the current study [22]. The potency of histamine to induced mini-Gq protein to the H1R was 10-fold lower as compared our BRET-based Gq activation sensor [26], which might be related to the one-to-one protein-protein interaction in the mini-Gq assay as opposite to possible activation of multiple heterotrimeric Gq proteins by a histamine-bound H1R in our BRET-based activation assay (i.e., signal amplification leading to receptor reserve).

Stimulation of H1R-expressing HEK293T cells with 10 µM histamine also rapidly increased InsP3 and Ca2+ levels to steady-state levels within 2 min as measured by ΔBRET changes of the InsP3 and Ca2+ biosensors, respectively, and this could be reversed by 10 µM H1R-antagonist mepyramine (Figure 1C,E). Similar agonist-induced time traces were observed for both these BRET-based InsP3 and Ca2+ biosensors in HEK293T cells expressing the angiotensin II receptor type 1 or muscarinic acetylcholine receptor M3 [23].

Histamine displayed a 10- and 16-fold higher potency to induce the InsP3 (pEC50 = 8.2 ± 0.8; mean ± SD; n = 4) and Ca2+ (pEC50 = 8.4 ± 0.2; mean ± SD; n = 4) response (Figure 1D,F), respectively, as compared to heterotrimeric Gq protein BRET sensor activation.

2.2. BRET-Based Detection of β-Arrestin1/2 Recruitment to H1R

GPCR signaling through heterotrimeric G proteins is generally modulated by the recruitment of β-arrestin1 and/or β-arrestin2 upon phosphorylation of the intracellular GPCR C-tail, resulting in steric hindrance of G protein coupling and subsequent internalization of the GPCR-β-arrestin complex by scaffolding clathrin and the AP2 adaptor [4,5].

In frame fusion of the optimized Renilla luciferase 8 (Rluc8) to the H1R C-terminal tail did not affect the binding affinity for radiolabeled [3H]mepyramine as compared to wildtype H1R (Supplementary Figure S1). Stimulation of HEK293T cells with histamine (10 µM) resulted in a gradual increase in ΔBRET between H1R-Rluc8 and both β-arrestin1-enhanced yellow fluorescent protein (eYFP) and β-arrestin2-mVenus to reach a steady-state level in approximately 1 h (Figure 2A), as previously observed for β-arrestin2 recruitment to this receptor [6,7]. Histamine induced β-arrestin2 recruitment to the H1R with comparable potency (pEC50 = 6.0 ± 0.3; mean ± SD; n = 4) as previously observed in BRET- and split-NLuc-based methods [6,9], whereas a slightly lower potency (pEC50 = 5.5 ± 0.5; mean ± SD; n = 4) was observed for β-arrestin1 recruitment (Figure 2B). In contrast, 41- and 55-fold higher potencies were observed in a click-beetle split-luciferase setup between H1R and β-arrestin1 and 2, respectively [30].

Pretreatment with the Gαq/11 protein inhibitor UBO-QIC (1 µM) [31] for 30 min did not significantly affect β-arrestin1/2 recruitment in response to 1-h stimulation with 10 µM histamine (Figure 2C), while completely abolishing histamine-induced nuclear factor activated T-cells (NFAT)-driven reporter gene activation in HEK293T cells expressing H1R-Rluc8 (Supplementary Figure S2). In contrast, 30-min pretreatment with the GRK2/3 inhibitor cmpd101 (3 µM) [32] resulted in a partial (~38–46%) but significant reduction in histamine-induced β-arrestin1/2 recruitment (Figure 2C), suggesting that GRK2/3-mediated phosphorylation of H1R might in part contribute to the interaction with β-arrestins, as previously observed for several other GPCRs [33–40]. Indeed, overexpression of GRK2 was reported to increase (180%) histamine-induced phosphorylation of H1R in HEK293 cells that were metabolically labeled with [32P]orthophosphate, whereas GRK5 and GRK6 increased H1R phosphorylation by 50 and 80%, respectively [11].
β-arrestin1/2 recruitment (ΔBRET Ratio)

Figure 2. Histamine (HA)-induced β-arrestin1/2 recruitment to H₁R. BRET measurements in HEK293T cells transiently co-expressing H₁R-Rluc8 (0.5 µg plasmid/dish) in combination with β-arrestin1-eYFP or β-arrestin2-mVenus (4.0 µg plasmid/dish) in real time upon stimulation with 10 µM histamine (A) or after 1-h stimulation with increasing concentrations histamine (B). Data are shown as mean ± SD from at least four independent experiments performed in triplicate. Area under the curve (AUC) of 1-h BRET traces in response to 10 µM histamine following 30-min pretreatment of the cells with vehicle (control), 3 µM cmpd101, or 1 µM UBO-QIC. AUC of the BRET experiments are presented as mean ± SD from three independent experiments performed in triplicate, with scatter plots (gray dots) showing the individual AUC values (C). Statistical differences (p < 0.05) compared to vehicle-pretreated (i.e., control) cells were determined using one-way ANOVA with Dunnett’s multiple comparison test and are indicated by an asterisk.

2.3. BRET-Based Detection of GRKs Interaction with H₁R

To evaluate which ubiquitously expressed GRK subtypes might potentially phosphorylate the histamine-activated H₁R and consequently promote β-arrestin1/2 coupling, a BRET assay was used to measure the interaction of H₁R with GRK2, GRK3, GRK5, and GRK6, as previously reported for the histamine H₂ receptor (H₂R) and the atypical chemokine receptor 3 (ACKR3) [33,39]. Histamine (10 µM) induced a very rapid increase in BRET between H₁R-Rluc8 and GRK2-mVenus or GRK3-mVenus that peaked within 2 min and subsequently decreased within 20 min to an elevated steady-state level as compared to vehicle-stimulated cells (Figure 3A). Hence, GRK2/3 interaction with activated H₁R indeed precedes the recruitment of β-arrestin1/2 in time, which was also previously reported for agonist-stimulated H₂R, atypical chemokine receptor 4 (ACKR4) oxytocin, and µ-opioid receptor [33,34,41,42], whereas GRK2/3 and β-arrestin1/2 were recruited with comparable kinetics to ACKR3 in response to chemokine CXCL12 stimulation [39]. On the contrary, histamine (10 µM) stimulation decreased BRET between H₁R-Rluc8 and GRK5-mVenus or GRK6-mVenus with slower kinetics as compared to the increased GRK2/3 interaction to this receptor, but comparable rates as the recruitment of β-arrestin1/2 (Figure 3A). The histamine-induced BRET decrease suggests that GRK5 and GRK6 are initially in proximity with H₁R and dissociate upon receptor activation, but the observed response may also reflect a change in conformational orientation between BRET donor and acceptor. In line, reduced BRET between agonist-activated receptor and GRK5 and/or GRK6 has been previously observed for H₂R, β₂-adrenergic receptor, bile acid receptor TGR5, neurokinin-1 receptor, and protease-activated receptor 2 [33,43–46]. In contrast, stimulation of ACKR3 with CXCL12 increased the BRET between this receptor and GRK5 [39]. No agonist-induced changes in BRET signal were observed for GRK6 with ACKR3 nor with bile acid receptor TGR5, and neither for GRK5/6 with ACKR4 [39,42,45].

The potencies of histamine to change the interaction between H₁R and GRKs 2, 3, 5, and 6 (pEC₅₀: 5.6 ± 0.1, 5.7 ± 0.1, 6.1 ± 0.1, and 6.0 ± 0.0, respectively; mean ± SD; n = 3) were comparable to its potencies to recruit β-arrestin1/2. Pretreatment of the HEK293T cells with Gₐ-inhibitor UBO-QIC (1 µM) for 30 min did not significantly affect the histamine-induced H₁R interaction with GRK2, 3, 5, and 6 (Figure 3C), indicating that these
interactions are independent of heterotrimeric G protein activation as previously shown for H₁R, β₂-adrenergic receptor, and dopamine D₂ receptor [33,36,47].

Figure 3. Histamine (HA)-induced modulation in H₁R interaction with GRKs. BRET measurements in HEK293T cells transiently co-expressing H₁R-Rluc8 (0.5 µg plasmid/dish) in combination with GRK2-mVenus, GRK3-mVenus, GRK5-mVenus, or GRK6-mVenus (4.0 µg plasmid/dish) in real time upon stimulation with 10 µM histamine (A) or after 1-h stimulation with increasing concentrations histamine (B). Data are shown as mean ± SD from at least three independent experiments performed in triplicate. Area under the curve (AUC) of 1-h BRET traces in response to 10 µM histamine following 30-min pretreatment of the cells with vehicle (control) or 1 µM UBO-QIC. AUC of the BRET experiments are presented as mean ± SD from three independent experiments performed in triplicate, with scatter plots (gray dots) showing the individual AUC values (C). No statistical differences (p < 0.05) compared to vehicle-pretreated (i.e., control) cells are observed using one-way ANOVA with Dunnett’s multiple comparison test.

2.4. H₁R Internalization Requires GRK2/3 and β-Arrestin1/2

H₁R is internalized upon stimulation with histamine with comparable kinetics as the recruitment of β-arrestin1/2, as measured by the increased BRET between H₁R-Rluc8 and the early endosome marker Venus-Rab5a (Figure 4A). Pretreatment of HEK293T cells with UBO-QIC, cmpd101, or siRNAs that decrease β-arrestin1/2 expression by 60% (Supplementary Figure S3), revealed that internalization of H₁R is independent of G₃ activation but requires GRK2/3 and β-arrestins (Figure 4B). Co-expression of a dominant-negative dynamin K⁴⁴A mutant or hypertonic conditions using 0.16 µM sucrose completely abolished histamine-induced H₁R translocation towards the early endosomes, indicating that H₁R internalization is clathrin-dependent as previously reported in transfected Chinese hamster ovary (CHO) cells [48].

Figure 4. Histamine (HA)-induced internalization of H₁R. BRET measurements in HEK293T cells transiently co-expressing H₁R-Rluc8 (0.5 µg plasmid/dish) in combination with the early endosome marker Venus-Rab5a (2 µg plasmid/dish) in real time upon stimulation with 10 µM histamine (A).
Data are shown as mean ± SD from at least three independent experiments performed in triplicate. Area under the curve (AUC) of 1-h BRET traces in response to 10 µM histamine following 30-min pretreatment of the cells with vehicle (control), 1 µM UBO-QIC, 3 µM cmpd101, or 0.16 µM sucrose, or co-transfection with dominant negative dynamin mutant K44A or β-arrestin1/2 siRNA. AUC of the BRET experiments are presented as mean ± SD from three independent experiments performed in triplicate, with scatter plots (gray dots) showing the individual AUC values (B). Statistical differences (p < 0.05) compared to vehicle-pretreated (i.e., control) cells were determined using one-way ANOVA with Dunnett’s multiple comparison test and are indicated by an asterisk.

2.5. Histamine H1R Agonists Display Distinct Efficacies in BRET-Based Responses in HEK293T Cells

The aforementioned BRET-based biosensors were then used to measure H1R activation by a selection of agonists (Supplementary Figure S4). Similar to reference agonist histamine, all tested agonists displayed higher potencies to activate Gq and in particular the increase in InsP3/Ca2+ levels, as compared to modulating H1R protein-protein interactions with GRK2, GRK3, GRK5, β-arrestin1, and β-arrestin2 (Figures 5 and 6A; Supplementary Table S1). Indeed, signal amplification has been previously reported for H1R-mediated G protein signaling but was not observed for one-to-one protein-protein interactions such as β-arrestin2 coupling [6]. The tested H1R agonists display comparable potencies (0.99- to 3.2-fold difference in EC50 values) between InsP3 and Ca2+ responses, whereas 5- to 37-fold lower potencies were observed for the activation of heterotrimeric Gq protein biosensor. However, Br-phHA had only a 1.7- and 5.4-fold lower potency to activate Gq as compared to Br-phHA-HA, CF3-phHA-HA, HP, and HPHA (0.6- to 2.5-fold) as compared to histamine (18- and 21-fold, respectively) and CF3-phHA-HA (85- and 36-fold, respectively) (Figure 6A; Supplementary Table S1). Interestingly, the difference in potency between GRK2/3 recruitment and Gq activation was smaller for Br-phHA, Br-phHA-HA, CF3-phHA-HA, HP, and HPHA (0.6- to 2.5-fold) as compared to histamine (18- and 21-fold, respectively) and CF3-phHA-HA (85- and 36-fold, respectively) (Figure 6A; Supplementary Table S1).

All tested H1R agonists acted as full agonists in InsP3 and Ca2+ signaling, whereas nearly full agonism (intrinsic activities relative to reference agonist histamine α > 0.9) was observed in Gq activation for Br-phHA-HA, CF3-phHA-HA, HP, and HPHA (Figures 5A–C and 6B; Supplementary Table S2). The higher intrinsic activities in InsP3/Ca2+ signaling as compared to Gq activation corroborate with the observed increase in potency downstream in the signaling pathway. Comparably high intrinsic activities were previously reported for HP (α = 0.8) and HPHA (α = 0.9) in H1R-mediated NF-κB-driven reporter gene activity in COS7 cells [49], for HP (α = 0.96) in inducing Gq-phospholipase C-β3 interaction in HEK293T cells [50], and for Br-phHA-HA (α = 0.94) and CF3-phHA-HA (α = 0.93) in a steady-state GTPase activity in Spodoptera frugiperda (SF9) cell membranes co-expressing human H1R and RGS4 [51]. In contrast, lower intrinsic activities were previously reported for HP (α = 0.62) and HPHA (α = 0.64) in this steady-state GTPase activity assay [52], and for HP (α = 0.33) in recruitment of mini-Gq protein to H1R in a luciferase-complementation assay to measure protein-protein interaction [26].

The intrinsic activities of Br-phHA and CF3-phHA to activate Gq activation were 0.7 ± 0.0 and 0.8 ± 0.0 (mean ± SD), respectively (Figure 6B; Supplementary Table S2), which were slightly higher than the α values that were previously observed in the steady-state GTPase activity assay (0.62 and 0.61, respectively) or CRE-driven reporter gene activity (0.56 and 0.62, respectively) [8,51]. As with the reference agonist histamine, both Br-phHA-HA and CF3-phHA-HA acted as full agonists in all used H1R assays, whereas Br-phHA, CF3-phHA, HP, and HPHA displayed clear partial agonism in GRK2/3 and β-arrestin1/2 recruitment (Figures 5 and 6B; Supplementary Table S2). In line, partial agonism was previously reported for Br-phHA, CF3-phHA, and HP in a luciferase-complementation-based assay to measure β-arrestin1/2 recruitment to H1R [8]. Interestingly, Br-phHA, CF3-phHA, HP, and HPHA might display a higher intrinsic activity to modulate the interaction of H1R with GRK5/6 as compared to GRK2/3 and β-arrestin1/2 (Figures 5 and 6B; Supplementary Table S2), although the low potencies of Br-phHA, CF3-phHA, and HP in GRK5/6 BRET assay did not allow accurate determination of their maximum responses.
The presented data in Figure 6A,B suggest signaling bias by some of the H1R agonists. For example, relative to reference agonist histamine, full agonist CF3-phHA-HA displays slightly higher potencies (2.4- to 4.0-fold) towards Gq, InsP3, Ca2+, and β-arrestin1/2, as compared to the GRK2/3/5/6 responses (1.0- to 2.0-fold higher), suggesting signaling bias towards the Gq-dependent responses. Oppositely, full agonist Br-phHA-HA shows slightly higher (1.7- to 3.2-fold higher than histamine) normalized potencies for GRK2/3 and β-arrestin1/2 in comparison to Gq-mediated responses (1.8- to 5-fold lower than histamine), suggesting signaling bias towards GRK2/3 and β-arrestin1/2. Interestingly, HPHA acted as a nearly full agonist in Gq-mediated responses with 2- to 5-fold lower normalized potencies as compared to histamine, but a partial agonist in the interaction with GRK2/3 and β-arrestins with 2.6- to 14-fold higher normalized potencies than histamine.

Figure 5. Concentration response curves of BRET-based responses in HEK293T cells upon stimulation with various H1R agonists. BRET measurements in HEK293T cells transiently co-expressing H1R (0.5–1.0 µg plasmid/dish) in combination with Gq activation sensor (2.5 µg plasmid/dish) (A), InsP3 (B) or Ca2+ (C) sensor (4.0 µg plasmid/dish), or H1R-Rluc8 (1.0 µg plasmid/dish) in combination with GRK2-mVenus (D), GRK3-mVenus (E), GRK5-mVenus (F), GRK6-mVenus (G), β-arrestin1-eYFP (H), or β-arrestin2-mVenus (I) (4.0 µg plasmid/dish), upon stimulation with increasing concentrations agonist for 20 (A–C) or 60 min (D–I). Data are shown as mean ± SD from at least three independent experiments performed in triplicate.
responses as compared to reference agonist histamine. However, histamine was more effective in Gq and GRK2 than Br-phHA-HA and CF3-phHA-HA, respectively. In contrast, Br-phHA, CF3-phHA, and HP displayed slightly lower relative effectiveness than histamine in most responses. Although Br-phHA-HA displayed lower relative effectiveness to induce heterotrimeric Gq biosensor activation versus all other tested responses, only a significant bias towards β-arrestin2 recruitment was observed. The relative effectiveness of CF3-phHA-HA to induced GRK2 recruitment to H1R was slightly lower as compared to all other tested responses, however, this difference found not to be statistically different. Hence, all H1R agonist-induced responses were compared to Gq activation by calculating the $\Delta\Delta\log(\tau/K_A)$ values to quantify bias (Figure 6E; Supplementary Table S5) [53–55].

**Figure 6.** Biased activities of agonists in BRET-based H1R responses in transfected HEK293T cells. The pEC$_{50}$ (A) and intrinsic activity (B) values obtained from the concentration response curves in Figure 5 (Supplementary Tables S1 and S2). Intrinsic activities were calculated versus reference full agonist histamine. Transduction ratio ($\log(\tau/K_A)$ (C), relative effectiveness ($\Delta\log(\tau/K_A)$) (D) and Log bias factor ($\Delta\Delta\log(\tau/K_A)$) (E) as calculated after analyzing the concentration response curves in Figure 5 using the operational model of agonism to retrieve the transduction ratio ($\log(\tau/K_A)$; Supplementary Table S3), followed by normalization to the reference full agonist histamine ($\Delta\log(\tau/K_A)$; Supplementary Table S4) and comparison of the various functional readouts to the Gq activation response ($\Delta\Delta\log(\tau/K_A)$; Supplementary Table S5). Data are shown as mean ± SD from at least three independent experiments performed in triplicate. Statistical differences ($p < 0.05$) between relative effectiveness of each ligand in the tested responses were determined using Welch ANOVA with Dunnett’s T3 multiple comparison test and are indicated by an asterisk.

To quantitatively compare the efficacy and potential signaling bias of these H1R agonists, all concentration-response data were analyzed using the operational model to retrieve a transduction ratio ($\tau/K_A$) for each ligand in each response (Figure 6C; Supplementary Table S3) [53,54]. The log ($\tau/K_A$) values for all agonists were first normalized to the log($\tau/K_A$) values of reference agonist histamine within each response to yield $\Delta\log(\tau/K_A)$ values as measure of relative effectiveness (Figure 6D; Supplementary Table S4).
Both Br-phHA-HA and CF3-phHA-HA displayed slightly higher relative effectiveness in most responses as compared to reference agonist histamine. However, histamine was more effective in G\textsubscript{q} and GRK2 than Br-phHA-HA and CF3-phHA-HA, respectively. In contrast, Br-phHA, CF3-phHA, and HP displayed slightly lower relative effectiveness than histamine in most responses. Although Br-phHA-HA displayed lower relative effectiveness to induce heterotrimeric G\textsubscript{q} biosensor activation versus all other tested responses, only a significant bias towards \(\beta\)-arrestin2 recruitment was observed. The relative effectiveness of CF3-phHA-HA to induced GRK2 recruitment to H\textsubscript{1}R was slightly lower as compared to all other tested responses, however, this difference found not to be statistically different. Hence, all H\textsubscript{1}R agonist-induced responses were compared to G\textsubscript{q} activation by calculating the \(\Delta\Delta\log(\tau/KA)\) values to quantify bias (Figure 6E; Supplementary Table S5) [53–55].

2.6. Histamine H\textsubscript{1}R Agonists Induced Ca\textsuperscript{2+} Mobilization in HeLa Cells Endogenously Expressing H\textsubscript{1}R

Finally, HeLa cells were stimulated with the H\textsubscript{1}R agonists to measure their efficacy in the rapid and transient Ca\textsuperscript{2+} mobilization via endogenous H\textsubscript{1}R using the Ca\textsuperscript{2+}-sensitive dye Fluo4NW (Figure 7A) [56]. Endogenous expression of H\textsubscript{1}R in HeLa cells (\(B_{max} = 150–200\) fmol/mg protein [24,56]) is approximately 20–34-fold lower as compared to HEK293T cells transfected with 1 \(\mu\)g H\textsubscript{1}R or H\textsubscript{1}R-Rluc8 plasmid (\(B_{max} = 3000–5000\) fmol/mg protein; data not shown). Not surprisingly, all ligands displayed less efficacy for Ca\textsuperscript{2+} mobilization in HeLa cells as compared to G\textsubscript{q}-activation responses in transfected HEK293T as revealed by their considerably lower pEC\textsubscript{50} values (>30-fold) for most ligands resulting in the (almost) absence of responsiveness to 100 \(\mu\)M Br-phHA and CF3-phHA, while responses by HP and HPHA did not allow accurate determination of their intrinsic activities (Figure 7B,C; Supplementary Tables S1 and S2). However, these lower efficacies in this fast and short term (within 20–30 s) Ca\textsuperscript{2+} response in HeLa cells as opposed to higher efficacies in the more prolonged responses (20–60 min) of the BRET-based assays in HEK293T cells might also be (in part) the consequence of binding kinetics of these agonists to the H\textsubscript{1}R, as observed for dopamine D2 receptor agonists [57]. Both CF3-phHA-HA and Br-phHA-HA displayed higher potency and intrinsic activities as compared to reference full agonist histamine (Figure 7B,C; Supplementary Table S2). In contrast to all other H\textsubscript{1}R agonists, Br-phHA-HA displayed only a 2-fold lower potency to induce Ca\textsuperscript{2+} mobilization in HeLa cells as compared to G\textsubscript{q}-activation in HEK293T cells (Supplementary Table S1). Similar to the BRET-based assays in HEK293T cells, CF3-phHA-HA and Br-phHA-HA displayed higher transduction ratios (log(\(\tau/KA\)) values and relative effectiveness (\(\Delta\log(\tau/KA)\) values) in Ca\textsuperscript{2+} signaling in HeLa cells in comparison to histamine, whereas transduction ratios and relative effectiveness values of HP and HPHA were lower (Figure 7D,E and Supplementary Table S4).

In conclusion, BRET-based assays were used to measure G\textsubscript{q} activation, InsP\textsubscript{3} and Ca\textsuperscript{2+} signaling, internalization, and interaction with GRKs2/3/5/6 and \(\beta\)-arrestins1/2 by the H\textsubscript{1}R in response agonist stimulation. Small differences in agonist efficacy were observed between some of these H\textsubscript{1}R responses. However, analysis of these functional responses using the operational model only revealed significant bias of a single agonist, BR-phHA-HA, towards \(\beta\)-arrestin2 recruitment over G\textsubscript{q} biosensor activation. Nevertheless, these BRET-based biosensors are valuable tools in the pharmacological characterization of H\textsubscript{1}R ligands that can be used in both real-time and end-point format at a reasonably high throughput.
were purchased from PerkinElmer (Waltham, MA, USA). Histaprodifen (HP), histaprodifen-(CF3-phHA-HA) were a gift from late prof. dr. Walter Schunack (Freie Universität Berlin, Germany) and also resynthesized at AstraZeneca (Macclesfield, UK), as previously described [58–60]. All other chemicals were of analytical grade and purchased from standard commercial suppliers. Cell culture plastics were purchased from Greiner Bio-One GmbH (Frickenhausen, Germany). Cmpd101 was purchased from Tocris Bioscience (Bristol, UK). Transfection reagent 25 kDa linear polyethylenimine (L-PEI) was bought from Polysciences (Danvers, MA, USA). Horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody was bought from Bio-Rad Laboratories (Hercules, CA, USA). [3H]mepixamine (specific activity 20.0 Ci/mmol), MicroScint-O scintillation liquid, and GF/C filter plates were purchased from PerkinElmer (Waltham, MA, USA). Histaprodifen (HP), histaprodifen-histamine dimer (HPHA; Nα-(imidazolylethyl)histaprodifen), 2-(3-bromophenyl)histamine (Br-phHA), 2-(3-bromophenyl)histamine-histamine dimer (Br-phHA-HA), 2-(3-trifluoromethylphenyl)histamine-histamine dimer (CF3-phHA-HA), 2-(3-trifluoromethylphenyl)histamine-histamine dimer (CF3-phHA-HA) were a gift from late prof. dr. Walter Schunack (Freie Universität Berlin, Berlin, Germany) and also resynthesized at AstraZeneca (Macclesfield, UK), as previously described [58–60]. All other chemicals were from analytical grade and purchased from standard commercial suppliers. Cell culture plastics were purchased from Greiner Bio-One GmbH (Frickenhausen, Germany).

3.2. DNA Constructs

Human histamine H1 receptor (H1R, GenBank: NM_00861), N-terminally hemagglutinin (HA)-tagged H1R, H1R-Rluc in pcDEF3 expression plasmid have been previously described [6]. Human histamine H1 receptor(H1R-Rluc8, β- arrestin1-eYFP, β-arrestin2-mVenus, GRK2-mVenus, GRK3-mVenus, GRK5-mVenus, and GRK6-mVenus in pcDEF3 have been previously described [33]. H1R-Rluc8/pcDEF3 was constructed by substitut-
ing the Rluc sequence in H1R-Rluc with the Rluc8 sequence from H4R-Rluc8 using NotI and XbaI restriction enzymes in the linker and 3’-end flanking sequences, respectively, and verified by DNA sequencing. Dominant-negative dynamin K44A and Venus-Rab5a plasmids were kindly provided by Dr. C van Koppen (Essen, Germany) and Dr. N. Lambert (Augusta, GA, USA), respectively [61,62]. The Ca2+ and inositol-1,4,5-triphosphate (InsP3) bioluminescence resonance energy transfer (BRET) sensors, Luc-D3-M13-cp173-Venus and Luc-IP3R-LBD-R265K-cp173-Venus [23], respectively, were a kind gift from Dr. P. Varnai (Budapest, Hungary). Tricistronic BRET-based Gq protein activation biosensors Gβ3-T2A-cpVenus-Gγ9-IRES-Gαq-Nluc was kindly provided by Dr. H. Schihada (Stockholm, Sweden) [22]. The reporter gene construct pNFAT-luc was obtained from Agilent Technologies (Santa Clara, CA, USA).

3.3. Cell Culture and Transfection

Human embryonic kidney 293T (HEK293T) cells (ATCC; Manassas, VA, USA) were maintained in DMEM supplemented with 10% FBS, 50 IU mL−1 penicillin and 50 mg mL−1 streptomycin in a humidified incubator at 37 °C with 5% CO2. HEK293T cells (2 × 106 cells/dish) were seeded in a 10 cm dish and transiently transfected the next day using the PEI method, as previously described [63]. To this end, plasmid DNA was mixed with 20 μg L-PEI (25 kDa) in 0.25 mL NaCl solution (150 mM) and incubated for 30 min at 22 °C before adding dropwise to a 10 cm dish with HEK293T cells. Total DNA amounts were kept at 5 μg by adding empty pcDEF3 plasmid. In β-arrestin knockdown experiments, HEK293T cells (4 × 105 cells/well) were seeded in a 6 well plate and transiently transfected the next day with plasmid DNA (2.5 μg) in combination with 50 nM β-arrestin1 and 50 nM β-arrestin2 siRNAs (1:1) or 100 nM scrambled siRNA using Lipofectamine 2000, as previously described [33]. HeLa cells were previously described [56].

3.4. Radioligand Binding Experiments

HEK293T cells were collected two days after transfection with 5 μg HA-H1R or H1R-Rluc8 plasmids per 10 cm dish in ice-cold phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4), centrifuged at 1900 × g for 10 min at 4 °C, and pellets were resuspended and homogenized on ice in binding buffer (50 mM Na2HPO4 and 50 mM KH2PO4, pH7.4) using a Branson sonifier 250 (Boom bv, Meppel, The Netherlands). The Protein levels in the cell homogenates was determined using the Pierce™ BCA protein assay kit. Cell homogenates (0.5–1.6 μg/well) were incubated with 0.5 to 80 nM [3H]mepyramine for 4 h at 22 °C with gentle agitation in the absence or presence of 10 μM mianserin to quantify total and nonspecific binding, respectively, as previously described [6]. Incubations were terminated by rapid filtration and 3 subsequent washes with ice-cold 50 mM Tris-HCl (pH 7.4) over 0.5% branched polyethyleneimine (750 kDa)-soaked GF/C filter plates using a 96 well FilterMate-harvester (PerkinElmer; Waltham, MA, USA). GF/C filter plates were dried at 52 °C for at least 3 h. Radioligand binding affinity (Kd) and total receptor numbers (Bmax) were determined by fitting the data to the “One-site–Total and nonspecific binding” model in GraphPad Prism version 8.4.3 (GraphPad Software, San Diego, CA, USA).

3.5. Nuclear Factor Activated T-cells (NFAT)-Driven Reporter Gene Assay

HEK293T cells were collected and seeded in poly-L-lysine-coated white 96-well plates (5 × 104 cells/well) one day after transfection with 1 μg HA-H1R in combination with 2.5 μg NFAT-luciferase reporter gene plasmids per 10 cm dish, as previously described with minor modifications [6]. The next day, cells were pre-incubated with 1 μM UBO-QIC or vehicle in serum-free DMEM for 30 min at 37 °C before stimulation with increasing concentrations histamine. The incubations were terminated after 6 h by replacing the medium with 25 μL luciferase assay reagent (0.83 mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 μM
Na2HPO4, 38.9 mM Tris-HCl (pH 7.8), 0.39% (v/v) glycerol, 0.03% (v/v) Triton X-100, and 2.6 µM dithiothreitol) and incubation for 30 min at 37 °C. Luminescence was measured (0.5 s/well) in Mithras LB940 multimode microplate reader (Berthold Technologies, Bad Wildbad, Germany).

3.6. Bioluminescence Resonance Energy Transfer (BRET) Assays

HEK293T cells were transiently co-transfected with 0.5–1 µg H1R-Rluc8 and 4 µg β-arrestin1-eYFP, β-arrestin2-mVenus, GRK2-mVenus, GRK3-mVenus, GRK5-mVenus, GRK6-mVenus, or 2 µg Venus-Rab5a plasmids per 10 cm dish. For the G protein-activation assay, HEK293T cells were transiently transfected with 0.5 µg H1R in combination with 2.5 µg Gβγ-T2A-cpVenus-Gγ9-IRES-Gαq-Nluc plasmids per 10 cm dish. To detect intracellular levels of InsP3 and Ca2+, HEK293T cells were transiently transfected with 0.5–1 µg H1R in combination with 4.0–4.5 µg Luc-D3-M13-cp173-Venus or Luc-IP3R-LBD-R265K-cp173-Venus plasmids per 10 cm dish. The next day, cells were collected and seeded in poly-L-lysine-coated white 96-well plates (5 × 10⁴ cells/well). Two days after transfection, basal BRET was measured between H1R-Rluc8 and the various eYFP/mVenus-fusion proteins using 5 µM coelenterazine-h in HBSS at 37 °C in the Mithras LB940 multimode microplate reader at 540–40 nm (acceptor) and 480–20 nm (donor) or the PHERAstar FS microplate reader (BMG Labtech; Ortenberg, Germany) at 535–30 nm (acceptor) and 475–30 nm (donor) followed by stimulation with H1R ligands, as previously described [33]. The G protein-activation sensor was measured in the Clariostar microplate reader (BMG Labtech; Ortenberg, Germany) at 535–30 nm monochromator (acceptor) and 470–80 nm monochromator (donor) using 3.2 µL/mL Nanoglo, as previously described [22,64]. The BRET ratio was first calculated for each well by dividing acceptor by donor light emission, and ligand-induced BRET ratio changes (ΔBRET) were subsequently calculated as ΔBRET = (BRET ratio_ligand − BRET ratio_vehicle)/BRET ratio_vehicle [7].

3.7. Western Blot

Western blot analysis to detect β-arrestin1/2 expression was performed as previously described [33]. Briefly, HEK293T cells were lysed in RIPA buffer (i.e., 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS) supplemented with 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4 and 1x cOmplete™ protease inhibitor cocktail for 20 min on ice, two days after transfection. Next, the lysates were sonicated for 5 s and centrifuged at 20,800 × g for 10 min at 4 °C. The samples were boiled at 95 °C for 5 min before SDS-PAGE electrophoresis using 10% resolving gels. Next, the proteins were transferred to Whatman® Westran® PVDF membranes and blocked for 1 h in 5% non-fat milk in 0.1% Tween-20/TBS solution at 22 °C. Protein expression was detected using primary antibodies anti-β-arrestin1/2 clone D24H9 (1:1000) and anti-STAT3 clone 79D7, followed by horseradish peroxidase-conjugated secondary antibody (1:5000).

3.8. Intracellular Ca2+ Mobilization in HeLa Cells

HeLa cells endogenously expressing the H1R were seeded in a clear-bottom 96-well plate (2 × 10⁴ cells/well). The next day, the cells were loaded with Fluo-4NW dye (1 vial/24 mL) for one hour in assay buffer (HBSS supplemented with 20 mM HEPES and 2.5 mM probenecid), subsequently washed twice to remove the excess of dye, and reconstituted in assay buffer. Fluorescence (excitation at 494 nm and emission at 516 nm) was measured every second in the NOVOstar microplate reader (BMG Labtech; Ortenberg, Germany) at 37 °C. First the background signal was measured (Fb), followed by the peak Ca2+ mobilization response 5–10 s after agonist injection (Fago), finally Triton X-100 (0.25% v/v) was injected 40 s later to quantify the maximum calcium levels by lysing the cells (Ft). The agonist-induced Ca2+ response was calculated as Δfluorescence = (Fago − Fb)/(Ft − Fb) [56].
3.9. Data Analysis

All results were analyzed using GraphPad Prism v8.4.3 (GraphPad Software, San Diego, CA, USA). Concentration-response curves were fitted using the “three parameters- log(agonist) vs. response” model:

\[
\text{response} = \text{bottom} + \frac{\text{top} - \text{bottom}}{1 + 10^{(\log EC_{50} - \log [A])}}
\]

Intrinsic activity (\(\alpha\)) value is calculated as:

\[
\alpha = \frac{\text{fitted maximum response agonist}}{\text{fitted maximum response histamine}}
\]

Concentration-response curves were globally fitted using the operational model to determine the transduction coefficient \(\log R\) \((R = \tau/K_A)\) as previously described [53–55], with \(\tau\) and \(K_A\) being the index of efficacy and functional equilibrium dissociation constant of the agonist, respectively:

\[
\text{response} = \text{basal} + \frac{(E_{\text{max}} - \text{basal})R^n[A]^n}{[A]^nR^n + \left(1 + \left[\frac{A}{K_A}\right]^n\right)}
\]

The \(\log R\) value of reference agonist histamine is subtracted from the \(\log R\) values of ligands for each specific response to obtain their relative effectiveness by eliminating the impact of cell- and assay-dependent effects [53–55]:

\[
\Delta \log R = \log R_{\text{ligand}} - \log R_{\text{histamine}}
\]

Standard deviation on the \(\Delta \log R\) is calculated using:

\[
SD_{\Delta \log R} = \sqrt{(SD_{\text{ligand}})^2 + (SD_{\text{histamine}})^2}
\]

Next, the \(\Delta \log R\) values of each ligand in the different functional responses were subtracted from its \(\Delta \log R\) value in \(G_q\) activation yielding \(\Delta \Delta \log R\) values to quantify signaling bias between \(G_q\) activation and the other responses (x). \(\Delta \Delta \log R\) values > 0 indicate bias towards \(G_q\) activation over the other responses (x) and vice versa for \(\Delta \Delta \log R\) values < 0 [53–55]:

\[
\Delta \Delta \log R = \Delta \log R_{G_q \text{activation}} - \Delta \log R_{\text{response}_x}
\]

Standard deviation on the \(\Delta \Delta \log R\) is calculated using:

\[
SD_{\Delta \Delta \log R} = \sqrt{(SD_{\Delta \log R_{G_q \text{activation}}})^2 + (SD_{\Delta \log R_{\text{response}_x}})^2}
\]

Welch ANOVA (does not assume equal variance) with a Dunnett’s T3 multiple comparisons test on the \(\Delta \log R\) values was used to determine the statistical significance of ligand activity between pathways, where \(p < 0.05\) was considered to be significant.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijms23063184/s1.

Author Contributions: Conceptualization, R.L. and H.F.V.; methodology, E.W.E.V., M.G., X.M., R.B. and S.M.d.M.; validation, E.W.E.V., M.G., R.B. and S.M.d.M.; formal analysis, H.F.V.; investigation, E.W.E.V., M.G., X.M., R.B., S.M.d.M., J.v.d.B. and B.A.A.; resources, R.L. and H.F.V.; data curation, E.W.E.V. and R.B.; writing—original draft, E.W.E.V. and H.F.V.; writing—review and editing, R.L., R.B. and H.F.V.; visualization, E.W.E.V., R.B. and H.F.V.; supervision, R.L. and H.F.V.; project administration, R.L. and H.F.V.; funding acquisition, R.L., H.F.V., X.M. and M.G. All authors have read and agreed to the published version of the manuscript.
References

1. Thurmond, R.L.; Gelfand, E.W.; Dunford, P.J. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nat. Rev. Drug Discov. 2008, 7, 41–53. [CrossRef]

2. Panula, P.; Chazot, P.L.; Cowart, M.; Gutzmer, R.; Leurs, R.; Liu, W.L.S.; Stark, H.; Thurmond, R.L.; Haas, H.L. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol. Rev. 2015, 67, 601–655. [CrossRef]

3. Tiligada, E.; Ennis, M. Histamine pharmacology: From sir Henry Dale to the 21st century. Br. J. Pharmacol. 2020, 177, 469–489. [CrossRef]

4. Gurevich, V.V.; Gurevich, E.V. GPCR signaling regulation: The role of GRKs and arrestins. [CrossRef]

5. Butcher, A.J.; Prihandoko, R.; Kong, K.C.; McWilliams, P.; Edwards, J.M.; Bottrill, A.; Mistry, S.; Tobin, A.B. Differential G-β-arrestin mediated trafficking and G protein-coupled receptor signaling. Mol. Pharmacol. 2016, 89, 65–74. [CrossRef]

6. Iwata, K.; Luo, J.; Penn, R.B.; Benovic, J.L. Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. J. Biol. Chem. 2005, 280, 2197–2204. [CrossRef]

7. Willets, J.M.; Taylor, A.H.; Shaw, H.; Konje, J.C.; Challiss, R.A.J. Selective regulation of H1 histamine receptor signaling by G protein-coupled receptor kinase 2 in uterine smooth muscle cells. Mol. Endocrinol. 2008, 22, 1893–1907. [CrossRef]

8. Wootten, D.; Christopoulos, A.; Marto-Solano, M.; Babu, M.M.; Sexton, P.M. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 2018, 27, 129. [CrossRef]

9. Wingler, L.M.; Lefkowitz, R.J. Conformational basis of G protein-coupled receptor signaling versatility. Trends Cell Biol. 2020, 30, 736–747. [CrossRef]

10. Latorraca, N.R.; Masureel, M.; Hollingsworth, S.A.; Heydenreich, F.M.; Suomivuori, C.-M.; Brinton, C.; Townshend, R.J.L.; Bouvier, M.; Kobilka, B.K.; Dror, R.O. How GPCR phosphorylation patterns orchestrate arrestin-mediated signaling. Cell 2020, 183, 1813–1825.e18. [CrossRef]

11. Butcher, A.J.; Prihandoko, R.; Kong, K.C.; McWilliams, P.; Edwards, J.M.; Bottrill, A.; Mistry, S.; Tobin, A.B. Differential G protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 2011, 286, 11506–11518. [CrossRef]

12. Yang, Z.; Yang, F.; Zhang, D.; Liu, Z.; Lin, A.; Liu, C.; Xiao, P.; Yu, X.; Sun, J.-P. Phosphorylation of G protein-coupled receptors: From the barcode hypothesis to the flute model. Mol. Pharmacol. 2017, 92, 201–210. [CrossRef]

13. Zidar, D.A.; Violin, J.D.; Whalen, E.J.; Lefkowitz, R.J. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl. Acad. Sci. USA 2009, 106, 9649–9654. [CrossRef]

14. Nobles, K.N.; Xiao, K.; Ahn, S.; Shukla, A.K.; Lam, C.M.; Rajagopal, S.; Strachan, R.T.; Huang, T.-Y.; Bressler, E.A.; Hara, M.R.; et al. Distinct phosphorylation sites on the β2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 2011, 4, ra51. [CrossRef]

15. Markham, A. Oliceridine: First approval. Drugs 2020, 80, 1739–1744. [CrossRef]
22. Schihada, H.; Shekhani, R.; Schulte, G. Quantitative assessment of constitutive G protein-coupled receptor activity with BRETh-based G protein biosensors. *Sci. Signal.* 2021, 14, eaaf1653. [CrossRef]

23. Gulyás, G.; Töth, J.T.; Töth, D.J.; Kurucz, I.; Hunyady, L.; Balla, T.; Vármai, P. Measurement of inositol 1,4,5-trisphosphate in living cells using an improved set of resonance energy transfer-based biosensors. *PLoS ONE* 2015, 10, e0125601. [CrossRef]

24. Adjobo-Hermans, M.J.W.; Goedhart, J.; van Weeren, L.; Nijmeijer, S.; Manders, E.M.M.; Offermans, S.; Gadella, T.W.J. Real-time visualization of heterotrimeric G protein Gq activation in living cells. *BMC Biol.* 2011, 9, 32. [CrossRef]

25. Van Unen, J.; Rashidfarrokhri, A.; Hoogendoorn, E.; Postma, M.; Gadella, T.W.J.; Goedhart, J. Quantitative single-cell analysis of signaling pathways activated immediately downstream of histamine receptor subtypes. *Mol. Pharmacol.* 2016, 90, 162–176. [CrossRef]

26. Höring, C.; Seibel, U.; Tropmann, K.; Grätz, L.; Mönnich, D.; Pitzl, S.; Bernhardt, G.; Pockes, S.; Strasser, A. A dynamic, split-luciferase-based mini-G protein sensor to functionally characterize ligands at all four histamine receptor subtypes. *Int. J. Mol. Sci.* 2020, 21, 8440. [CrossRef]

27. Nehm, R.; Carpenter, B.; Singhal, A.; Strege, A.; Edwards, P.C.; White, C.F.; Du, H.; Grisshammer, R.; Tate, C.G. Mini-G proteins: Novel tools for studying GPCRs in their active conformation. *PLoS ONE* 2017, 12, e0175642. [CrossRef]

28. Inoue, A.; Raimondi, F.; Kadij, F.M.N.; Singh, G.; Kishi, T.; Uwamizu, A.; Ono, Y.; Shinjo, Y.; Ishida, S.; Arang, N.; et al. Illuminating G-protein-coupling selectivity of GPCRs. *Cell* 2019, 177, 1933–1947.e25. [CrossRef]

29. Olsen, R.H.J.; DiBerto, J.F.; English, J.G.; Glaudin, A.M.; Krumm, B.E.; Slocum, S.T.; Che, T.; Gavin, A.C.; McCorvy, J.D.; Roth, B.L.; et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. *Nat. Chem. Biol.* 2020, 16, 841–849. [CrossRef]

30. Lieb, S.; Littmann, T.; Plank, N.; Felixberger, J.; Tanaka, M.; Schäfer, T.; Krief, S.; Elz, S.; Friedland, K.; Bernhardt, G.; et al. Label-free versus conventional cellular assays: Functional investigations on the human histamine H1 receptor. *Pharmacol. Res.* 2016, 114, 13–26. [CrossRef]

31. Schrage, R.; Schmitz, A.-L.; Gaffal, E.; Annala, S.; Kehraus, S.; Wenzel, D.; Büellesbach, K.M.; Bald, T.; Inoue, A.; Shinjo, Y.; et al. The experimental power of FR900359 to study Gq-regulated biological processes. *Nat. Commun.* 2015, 6, 10156. [CrossRef]

32. Thal, D.M.; Yeow, R.Y.; Schoenau, C.; Huber, J.; Tesmer, J.J.G. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. *Mol. Pharmacol.* 2011, 80, 294–303. [CrossRef]

33. Verweij, E.W.E.; Al Araaj, B.; Prabhata, W.R.; Nijmeijer, S.; Tobin, A.B.; Leurs, R.; Vischer, H.F. Differential role of serines and threonines in intracellular loop 3 and C-terminal tail of the histamine H4 receptor. *Mol. Pharmacol.* 2011, 80, 881–891. [CrossRef] [PubMed]

34. Lowe, J.D.; Sanderson, H.S.; Cooke, A.E.; Ostovar, M.; Tsissanova, E.; Withey, S.L.; Chavkin, C.; Husbands, S.M.; Kelly, E.; Henderson, G.; et al. Role of G protein-coupled receptor kinases 2 and 3 in µ-opioid receptor desensitization. *Sci. Signal.* 2018, 11, eaas9609. [CrossRef] [PubMed]

35. Drube, J.; Haider, R.S.; Matthees, E.F.; Reichel, M.; Zeiner, J.; Fritzwaniker, S.; Ziegler, C.; Barz, S.; Klement, L.; Filor, J.; et al. GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation. *Nat. Commun.* 2022, 13, 540. [CrossRef]

36. Pack, T.F.; Orlen, M.I.; Ray, C.; Peterson, S.M.; Caron, M.G. The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation. *J. Biol. Chem.* 2018, 293, 6161–6171. [CrossRef]

37. Shintani, Y.; Hayata-Takano, A.; Moriguchi, K.; Nakazawa, T.; Aoyagi, Y.; Kasai, A.; Seiriki, K.; Shintani, N.; Hashimoto, H. β-arrestin1 and 2 differentially regulate PACAP-induced PAC1 receptor signaling and trafficking. *PLoS ONE* 2018, 13, e0196946. [CrossRef] [PubMed]

38. Drube, J.; Haider, R.S.; Matthees, E.F.; Reichel, M.; Zeiner, J.; Fritzwaniker, S.; Ziegler, C.; Barz, S.; Klement, L.; Filor, J.; et al. GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation. *Nat. Commun.* 2022, 13, 540. [CrossRef]

39. Zara, A.; Perez, C.; van den Bor, J.; Beelman, J.P.; Heuninck, J.; de Jonker, R.J.F.; Durroux, T.; Vischer, H.F.; Siderius, M.; Smit, M.J. Differential involvement of ACKR3 C-tail in β-arrestin recruitment, trafficking and internalization. *Cells* 2021, 10, 618. [CrossRef]

40. Møller, T.C.; Pedersen, M.F.; van Senten, J.R.; Seiersen, S.D.; Mathiesen, J.M.; Bouvier, M.; Bräuner-Osborne, H. Dissecting the roles of GRK2 and GRK3 in µ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells. *Sci. Rep.* 2020, 10, 17395. [CrossRef]

41. Hasbi, A.; Devost, D.; Laporte, S.A.; Zingg, H.H. Real-time detection of interactions between the human oxytocin receptor and G protein-coupled receptor kinase-2. *Mol. Endocrinol.* 2004, 18, 1277–1286. [CrossRef]

42. Matti, C.; Salnikov, A.; Artinger, M.; D’Agostino, G.; Kindler, I.; Uggionni, M.; Thelen, M.; Legler, D.F. ACKR4 recruits GRK3 prior to β-arrestins but can scavenge chemokines in the absence of β-arrestins. *Front. Immunol.* 2020, 11, 720. [CrossRef]

43. Tran, T.M.; Jorgensen, R.; Clark, R.B. Phosphorylation of the β3-adrenergic receptor in plasma membranes by intrinsic GRK5. *Biochemistry* 2007, 46, 14438–14449. [CrossRef]

44. Jorgensen, R.; Holliday, N.D.; Hansen, J.L.; Vredel, M.; Heding, A.; Schwartz, T.W.; Elling, C.E. Characterization of G-protein coupled receptor kinase interaction with the neurokinin-1 receptor using bioluminescence resonance energy transfer. *Mol. Pharmacol.* 2008, 73, 349–358. [CrossRef]
57. Klein Herenbrink, C.; Sykes, D.A.; Donthamsetti, P.; Canals, M.; Coudrat, T.; Shonberg, J.; Scammells, P.J.; Capuano, B.; Sexton, P.M.; Charlton, S.J.; et al. The role of kinetic context in apparent biased agonism at GPCRs. *Nat. Commun.* 2016, 7, 10842. [CrossRef] [PubMed]

58. Leschke, C.; Elz, S.; Garbarg, M.; Schunack, W. Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues. *J. Med. Chem.* 2013, 56, 5458–5470. [CrossRef] [PubMed]

59. Menghin, S.; Pertz, H.H.; Kramer, K.; Seifert, R.; Schunack, W.; Elz, S. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: Synthesis and in vitro evaluation of highly potent histamine H1-receptor agonists. *J. Med. Chem.* 2000, 43, 1071–1084. [CrossRef] [PubMed]

60. Menghin, S.; Pertz, H.H.; Kramer, K.; Seifert, R.; Schunack, W.; Elz, S. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: Synthesis and in vitro evaluation of highly potent histamine H1-receptor agonists. *J. Med. Chem.* 2003, 46, 5458–5470. [CrossRef] [PubMed]

61. Vögler, O.; Bogatkewitsch, G.S.; Wriske, C.; Krummener, P.; Jakobs, K.H.; van Koppen, C.J. Receptor subtype-specific regulation of muscarinic acetylcholine receptor sequestration by dynamin. Distinct sequestration of m2 receptors. *J. Biol. Chem.* 1998, 273, 12155–12160. [CrossRef] [PubMed]

62. Lan, T.-H.; Kuravi, S.; Lambert, N.A. Internalization dissociates β2-adrenergic receptors. *PLoS ONE* 2011, 6, e17361. [CrossRef] [PubMed]

63. Ma, X.; Segura, M.A.; Zarzycka, B.; Vischer, H.F.; Leurs, R. Analysis of missense variants in the human histamine receptor family reveals increased constitutive activity of E4106.30 × 30K variant in the histamine H1 receptor. *Int. J. Mol. Sci.* 2021, 22, 3702. [CrossRef] [PubMed]

64. Ma, X.; Verweij, E.W.E.; Siderius, M.; Leurs, R.; Vischer, H.F. Identification of TSPAN4 as novel histamine H4 receptor interactor. *Biomolecules* 2021, 11, 1127. [CrossRef] [PubMed]